Hemp Stocks

841 posts / 0 new
Letzter Beitrag
Ben
Bild des Benutzers Ben
Offline
Zuletzt online: 17.05.2019
Mitglied seit: 11.01.2010
Kommentare: 628
ACB/USA/D. T.

Ich habe hier noch eine interessante Aussage von Donald Trump:

“We are looking at letting states decide legalization. 

I will probably end up supporting that, yes. „ D  T  

(Wir prüfen, ob Staaten eine Legalisierung zulassen. Ich werde wahrscheinlich am Ende das unterstützen, ja. )

Aber, man weiss auch, dass er wie die Fahne im Wind ist.

Quelle: Newsweek vom 31.08.2018 newsweek.com

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 16.05.2019
Mitglied seit: 16.04.2010
Kommentare: 1'415
ACB/Aurora

@Ben

Dann ist ja gut, werden die ACB nicht in USA gehandelt! Wie auch immer, dort wird's schlimmer. Smile WinkDirol

Link
Bild des Benutzers Link
Offline
Zuletzt online: 16.05.2019
Mitglied seit: 20.12.2011
Kommentare: 4'502
GOLDSCHWÄCHE

GOLDSCHWÄCHE

Uhi, geht da bald CFM Konkurs?

 

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 06.05.2019
Mitglied seit: 06.06.2011
Kommentare: 692
Auroa-News heute

Aurora / ACB

News

Aurora Cannabis Completes Distribution of Australis Capital

EDMONTON, Sept. 19, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM), today announced that it has completed its previously announced distribution of Australis shares and warrants (the "Distribution"). The distribution was completed on September 19, 2018,  and the Australis shares and warrants will commence trading on the CSE under the symbol "AUSA" effective at the market open today.

In accordance with the terms of the Distribution, eligible Aurora shareholders were paid one unit of Australis for every 34 Aurora shares outstanding as at August 24, 2018 (the "Record Date). Each unit consists of one common share and one share purchase warrant of Australis. Each warrant entitles the holder thereof to acquire one share at an exercise price of $0.25 per Australis share, on or prior to 4:00 p.m. (Eastern Time) on the date that is one year after the Distribution.

As described in further detail in the Final Prospectus, no units were issued to shareholders who are (or were deemed to be) non-residents of Canada. Rather, such units have been delivered to a custodian for sale in the open market following the Distribution, and the net cash proceeds will be delivered to non-resident shareholders, net of any withholding taxes. 

Following the distribution, Aurora has no direct ownership interest in Australis, and the company is an independently operating entity. Aurora, however, does hold two warrants, allowing the Company to acquire an ownership interest at such time in the future (within 10 years) when holding investments in U.S. cannabis assets will become permissible.

"With the completion of this distribution we have delivered an immediate return of capital to Aurora shareholders while enabling the Australis team to proceed with their mandate to invest in U.S. cannabis assets with high growth potential," said Terry Booth, CEO of Aurora. "Australis' management, board of directors and investment committee are well positioned to leverage their collective knowledge and extensive experiences to rapidly execute on the tremendous opportunity ahead to generate substantial long-term shareholder value."

Scott Dowty, CEO of Australis, added, "We will leverage the opportunities created by a fragmented U.S. cannabis market with limited access to growth capital. We have not wasted time and have already identified a number of strong assets within this market that we believe have high growth potential. With the completion of our over-subscribed private placement, we have the funds to start executing on these opportunities immediately and deliver growth." 

About Aurora 

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per year and sales and operations in 18 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at ultra-low costs. Intended to be replicable and scalable globally, these production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and ultra-low per gram production costs. Each of Aurora's facilities is built to meet European Union (EU) GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland (formerly Pedanios), have achieved this level of certification.

In addition to the Company's rapid organic growth and strong execution on strategic M&A, which to date includes 15 companies – MedReleaf, CanvasRX, Peloton Pharmaceutical,  Aurora Deutschland (formerly Pedanios), H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, Agropro, Borela, and the pending acquisition of ICC Labs – Aurora is distinguished by its reputation as a partner of choice and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: The Green Organic Dutchman Holdings Ltd. (TSX: TGOD), Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Namaste Technologies Inc. (TSXV: N), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website, investor.auroramj.comTwitterFacebook or Instagram

Terry Booth, CEO
Aurora Cannabis Inc.

About Australis

Australis Capital identifies and invests in the cannabis industry predominately in the United States, a highly regulated, fragmented, fast growing and evolving industry. Investments may include and are not limited to equity, debt or other securities of both public and private companies, financings in exchange for royalties or other distribution streams, and control stake acquisitions. Australis Capital adheres to stringent investment criteria and will focus on significant near and mid-term high-quality opportunities with strong return potentials while maintaining a steadfast commitment to governance and community. Australis Capital's Board, Management and Advisory Committee members have material experience with, and knowledge of, the cannabis space in the U.S., extensive backgrounds in highly regulated industries, adherence to stringent regulatory compliance, public company and operational expertise. For more information, please visit us at www.ausacap.com.

 

und

Presse: / Quelle:

https://www.profitconfidential.com/stock/aurora-cannabis-stock/otcmkts-acbff-stock-forecast-post-hemp-leadership-europe-coca-cola-us-listing-october/

 

Coca-Cola Partnership

It’s been a hectic week for marijuana stocks so far, with a lot of news dropping on a variety of fronts. But none has been more impactful than the rumors that The Coca-Cola Co (NYSE:KO) is looking to enter the marijuana industry and could choose Aurora Cannabis Inc (OTCMKTS:ACBFF, TSE:ACB) as its vessel. Needless to say, the potential Coca-Cola partnership proved to be a massive boon to the Aurora stock forecast.

Reports have come in that Coca-Cola is in talks with Aurora to produce non-alcoholic, cannabis-infused beverages. As a result, Aurora Cannabis stock climbed swiftly, surging 10% when the reports came in, while KO stock hasn’t seen much movement since the talks were announced. (Source: “Coke, Aurora Cannabis in talks to make marijuana-infused drinks: BNN Bloomberg,” CNBC, September 17, 2018.)

Should the partnership come to fruition, the two would likely develop health-focused beverages that will ease inflammation, pain, and cramping, the report stated.

“Along with many others in the beverage industry, we are closely watching the growth of non-psychoactive CBD [cannabidiol] as an ingredient in functional wellness beverages around the world,” The Coca-Cola Co said in a statement. “No decisions have been made at this time.”

Advertisement

Aurora also declined to give specifics about a potential deal, but did say that it, “has expressed specific interest in the infused beverage space, and we intend to enter that market.” (Source: Ibid.)

This marks the first time a non-alcoholic beverage company has looked into the marijuana sector.

Considering how positive investments have been received by the alcohol industry, the soft-beverage sector now looking to enter the marijuana market is only going to drive marijuana stock prices even higher.

After all, the $3.8-billion investment by Constellation Brands, Inc. (NYSE:STZ) into Canopy Growth Corp (NYSE:CGC) was enough to turn the entire industry around and push dozens of percentage points of growth across multiple stocks.

Should Coca-Cola be planning to invest, expect to see a major surge in marijuana prices as more concrete details filter out.

But the potential Coca-Cola deal is not the only positive news to have come out of Aurora Cannabis stock lately.

While likely to be the most momentous, several other positive moves by the company have brightened the Aurora Cannabis stock forecast considerably.

Hemp Leadership in Europe

One of the more recent boons to the Aurora Cannabis stock forecast came by way of the company’s deal with Agropro UAB, Europe’s largest producer, processor, and supplier of organic hemp and hemp products.

The Agropro acquisition provides Aurora with access to 1,600 hectares of land to grow a potential 1,000,000 kilograms of hemp, while Agropro is also looking into expanding into Lithuania, Latvia, Estonia, and Poland, potentially adding another 3,000 hectares. (Source: “Aurora Cannabis Acquires Europe’s Largest Organic Hemp Company,” Cision, September 12, 2018.)

The deal will open up Agropro to exploiting the CBD components of its hemp.

Aurora is planning to use that formerly discarded hemp biomass containing CBD to create a number of wellness products.

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 10.04.2019
Mitglied seit: 28.09.2007
Kommentare: 3'114
Aurora und CocaCola

Ben hat am 17.09.2018 22:43 geschrieben:

CocaCola möchte Cannabis-Drinks herstellen und befindet sich offenbar in Gesprächen mit Aurora. Die Gespräche sollen weit fortgeschritten sein. 

Quelle: ntv

17.09.2018 20:36

Offenbar Gespräche mit Aurora

Coca-Cola will Cannabis-Drinks herstellen

Die Gespräche laut Insidern seien "ziemlich weit fortgeschritten".

(Foto: dpa)

An alkoholische Getränke hat sich Softdrink-Riese Coca-Cola bereits herangewagt. Nun will der Konzern einem Medienbericht zufolge auch cannabishaltige Drinks entwickeln. Sie sollen gegen Schmerzen und Krämpfe wirken.

 

            
 

Coca-Cola hat offenbar Interesse am Einstieg in die Herstellung von cannabishaltigen Getränken. Dem kanadische Business-Sender "BNN Bloomberg" zufolge verhandelt der Konzern diesbezüglich mit Aurora, einem der größten kanadischen Cannabis-Hersteller. Die Nachricht versetzte Aurora-Anleger sogleich in einen Kaufrausch: Die Aktien stiegen an der Börse in Toronto um bis zu 22 Prozent auf 10,42 Dollar. 

 

Coca-Cola und Aurora teilten in getrennten Erklärungen mit, man schaue sich die Entwicklung am wachsenden Markt von mit Marihuana versetzten Getränken genau an. Ansonsten kommentiere man aber keine Marktspekulationen. Auch "BNN Bloomberg" zufolge gibt es keine Garantie dafür, dass die Gespräche erfolgreich verlaufen. Die beiden Unternehmen werden demnach wahrscheinlich aber Drinks entwickeln, die bei Schmerzen, Entzündungen und Krämpfen wirken, meldete der Sender unter Berufung auf Insider. Die Gespräche seien "ziemlich weit fortgeschritten".

Bei den mit Marihuana versetzten Getränken geht es um den Wirkstoff Cannabidiol (CBD), der als nicht suchtfördernd oder berauschend gilt. Dem Deutschen Hanfverband zufolge gilt CBD zudem als relativ arm an Nebenwirkungen. Als Ausnahmemedikation bei schweren Erkrankungen kann Cannabis in Deutschland seit März letzten Jahres gegen Schmerzen verordnet werden. Aus der Hanfpflanze wird aber auch das "high" machende Tetrahydrocannabinol (THC) gewonnen. 

Kanada und einige US-Bundesstaaten haben Marihuana auch für nicht medizinische Zwecke als Genussmittel legalisiert. Nach dem US-Bundesrecht bleibt der Handel damit aber verboten, weshalb viele US-Konzerne vorsichtig sind. 

Bisher haben sich nur Alkohol-Hersteller auf den Markt vorgewagt. So hat der Hersteller von Corona-Bier Constellation Brands mehr als vier Milliarden Dollar in Canopy Growth - ebenfalls aus Kanada - investiert, um auf Cannabis basierende Getränke zu produzieren. Analysten rechnen nun damit, dass auch der Cola-Rivale Pepsi an dem Markt interessiert sein dürfte.

CHARTS


Aurora Cannabis
6,59   19,8%

ftü/DJ

 

Hi, da haben noch andere was gecheckt, Quelle Link:

https://seekingalpha.com/article/4206884-aurora-cannabis-one-just-right

Aurora Cannabis: This One Is "Just Right"

Sep. 18, 2018 10:13 AM ET

|

| About: Aurora Cannabis Inc. (ACBFF), KO, Includes: APHQF, CGC, CRON, HMLSF, HYYDF, MJ, TGODF, TLRY

by: Jonathan Cooper

Jonathan Cooper

Long/short equity, growth at reasonable price, contrarian, long-term horizon

Marketplace

The Growth Operation

(4,773 followers)

Summary

Perhaps Aurora is the "just right" combination of Canopy Growth's execution with HEXO's low price.

Good execution: deals with major pharmacies, growing medical marijuana sales, supply agreements covering 89% of Canadians.

I have some concerns about Aurora's acquisition spree.

A Coca-Cola deal and a US stock listing could be great tailwinds in the coming months.

I rate Aurora as a buy and it remains a smaller holding in my Model Cannabis Portfolio.

Looking for a portfolio of ideas like this one? Members of The Growth Operation get exclusive access to our model portfolio. Start your free trial today »

(All prices are in Canadian dollars.)

Canadian cannabis companies by production capacity

(Author based on company filings; some figures are estimates as, e.g., Canopy Growth does not provide production estimates in kg/year)

Executive Summary

Aurora Cannabis (ACB.TO) (OTCQX:ACBFF) is the third-largest Canadian cannabis company by enterprise value and the second-largest by production capacity and supply agreements.

Aurora has grown aggressively through acquisitions. Aurora took an 18% stake in The Green Organic Dutchman (OTCQX:TGODF) in January, acquired CanniMed in March, and MedReleaf in July. The latter two deals were the largest of their kind when they were made. These acquisitions are double-edged: They allow Aurora to expand rapidly, but they present a risk that Aurora may overpay and destroy shareholder value.

Aurora rose heavily on September 17 on rumors of a deal with Coca-Cola (KO). In the short term, that deal - and whether it happens or not - is likely to have a big impact on Aurora's share prices. Shares gained 17% on the rumor and could fall just as far if KO makes a deal elsewhere. Shares could also rise further if the right deal is announced: Canopy Growth (CGC) rose over 30% on August 15th after the Constellation (STZ) deal.

In terms of value, Aurora occupies a middle ground in between the inexpensive Aphria (OTCQB:APHQF) and HEXO (OTCPK:HYYDF) and the premium valuations of Canopy Growth, Tilray (TLRY), and Cronos (CRON). Perhaps Aurora is the Goldilocks of Canadian cannabis stocks - a "just right" combination of the value of HEXO with the size and execution (deals in the top four provinces and with large pharmacies) of Canopy Growth.

 

und

https://www.streetinsider.com/Corporate+News//Aurora+Cannabis+Responds+to+Media+Reports+on+Rumored+Partnership+with+Beverage+Companies+%28KO%29/14618584.html

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM), today is responding to a request from the Investment Industry Regulatory Organization of Canada ("IIROC") regarding media reports with respect to potential partnerships with multiple beverage companies. The Company's policy is not to comment on speculative media reports. The Company does confirm that it engages in exploratory discussions with industry participants from time to time. At this time the Company confirms there is no agreement, understanding or arrangement with respect to any partnership with a beverage company.

In accordance with applicable disclosure requirements, Aurora will advise the market of material changes when they occur.

 

 

Emil

Tengri Lethos
Bild des Benutzers Tengri Lethos
Offline
Zuletzt online: 19.05.2019
Mitglied seit: 10.11.2013
Kommentare: 1'289
VIDEO: Maydorns Meinung:

VIDEO: Maydorns Meinung: Tilray, Aurora Cannabis

(BYD, Tesla, Daimler, Commerzbank, Evotec, Medigene)

http://www.deraktionaer.tv/video/maydorns-meinung-tilray-aurora-cannabis...

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 16.05.2019
Mitglied seit: 16.04.2010
Kommentare: 1'415
Aurora Investor Conference Call Sept.25, 2018

Danke at Tengri Lethos für Video

Aurora Cannabis to Host Fourth Quarter 2018 Investor Conference Call on September 25, 2018

TSX: ACB

EDMONTON, Sept. 21, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM), today announced that it has scheduled its conference call to discuss the results for its fourth quarter ended June 30, 2018. The call will be hosted on Tuesday, September 25th, 2018 at 11:00 a.m. Eastern Timeby Terry Booth, Chief Executive Officer, Glen Ibbott, Chief Financial Officer, and Cam Battley, Chief Corporate Officer followed by a question and answer period.

 

CONFERENCE CALL DETAILS

 

DATE:

Tuesday, September 25th, 2018

TIME:

11:00 a.m. Eastern Time (9:00 a.m. Mountain Time)

WEBCAST:

https://bit.ly/2pnnKkA

DIAL IN NUMBER:

(647) 427-7450 or (888) 231-8191

REPLAY:

(416) 849-0833 or (855) 859-2056
Available until 12:00 midnight Eastern Time Tuesday, October 2, 2018

REFERENCE NUMBER:

2977713

About Aurora 

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per year and sales and operations in 18 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at ultra-low costs. Intended to be replicable and scalable globally, these production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and ultra-low per gram production costs. Each of Aurora's facilities is built to meet European Union (EU) GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland (formerly Pedanios), have achieved this level of certification.

In addition to the Company's rapid organic growth and strong execution on strategic M&A, which to date includes 15 companies – MedReleaf, CanvasRX, Peloton Pharmaceutical,  Aurora Deutschland (formerly Pedanios), H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, Agropro, Borela, and the pending acquisition of ICC Labs – Aurora is distinguished by its reputation as a partner of choice and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: The Green Organic Dutchman Holdings Ltd. (TSX: TGOD), Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Namaste Technologies Inc. (TSXV: N), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website, investor.auroramj.comTwitterFacebook or Instagram

Terry Booth, CEO
Aurora Cannabis Inc.

Tengri Lethos
Bild des Benutzers Tengri Lethos
Offline
Zuletzt online: 19.05.2019
Mitglied seit: 10.11.2013
Kommentare: 1'289
VIDEO: Marktüberblick: Tilray

VIDEO: Marktüberblick: (ab Min. 5.20) Tilray, Aurora Cannabis

(Dow Jones, DAX, Kupfer, Alibaba, BYD, Tom Tailor, Rocket Internet)

http://www.deraktionaer.tv/video/marktueberblick-dow-jones-dax-kupfer-al...

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 10.04.2019
Mitglied seit: 28.09.2007
Kommentare: 3'114
ACB / Aurora Results Q4-2018 und Fical Year 2018

Danke at Shanik82 für Info oben.

Aurora s. Link, Text ist lang, aber super  *clapping*:

https://www.newswire.ca/news-releases/aurora-cannabis-inc-announces-results-for-the-fourth-quarter-and-2018-fiscal-year-694175781.html

 

Presse / Kurzfassung:

By

Published: Sept 24, 2018 6:10 p.m.  

Tech reporter

Aurora Cannabis Inc. ACBFF, +2.64% ACB, +3.63% released fiscal fourth-quarter earnings late Monday and confirmed its intention to list stock on a "senior" U.S. exchange such as the Nasdaq or the New York Stock Exchange. "Listing our shares on a senior U.S. exchange reflects the level of corporate and business maturity and our high-paced execution," Aurora Chief Executive Terry Booth said. "This listing provides access to a broader investor audience who gain the opportunity to participate in our continued success." The company's top line grew 223% to C$19.1 million, up from C$5.9 million in the year-earlier quarter. Aurora logged earnings of C$79.9 million, up from losses of C$4.8 million in last year's quarter; in its financial statements Aurora said the quarter's profits were related to unrealized non-cash gains on derivatives and other marketable securities. Gross profit was C$20.6 million, up from C$5.8 million in the year-ago quarter. The company said it produced 2,212 kilograms of pot and sold 1,617 kilograms, up 90% and 114% respectively compared with the year-earlier period. Aurora stock is listed on the pink sheets in the U.S. and on the TSX. Toronto-listed shares have gained 28% this year, as the S&P 500 index SPX, -0.35% rose 9.2%.

Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.

Quelle:https://www.marketwatch.com/story/aurora-cannabis-releases-earnings-confirms-us-listing-plans-2018-09-24?mod=newsviewer_click

 

Emil

shanik82
Bild des Benutzers shanik82
Offline
Zuletzt online: 24.09.2018
Mitglied seit: 14.01.2015
Kommentare: 35
Cannmart receives Health Canada's first ACMPR sales-only license

Namaste Technologies Inc. ("Namaste" or the "Company") (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company's wholly-owned subsidiary, Cannmart Inc. ("Cannmart") has received its Access to Cannabis for Medical Purposes Regulations ("ACMPR") medical cannabis "sales-only" license (the "License"), which is the first of its kind to be issued by Health Canada. The License represents the most significant milestone in the history of the Company and is the final component of its strategy for Cannmart to become Canada's leading online platform for medical cannabis.

Cannmart will operate as an online marketplace for medical cannabis sourced from multiple Licensed Producers, which will offer patients a curated selection of medical cannabis strains in one location. Cannmart has secured over 13 domestic and international supply agreements and will also focus on developing arrangements with micro-cultivators who will provide high-end craft strains, subject to the upcoming regulations of the Cannabis Act. Cannmart's goal is to offer the largest and most diverse selection of medical cannabis products available in the Canadian market.

Further to the Company's September 18(th) news release, Cannmart will be allowed to buy pre-packaged, labelled and tested cannabis products. This development is very significant for Cannmart in that it will eliminate the need for buying in bulk, testing and packaging which will significantly reduce overhead costs for Cannmart and thus increase gross profit margins and profitability. By allowing Cannmart to purchase pre-packaged medical cannabis products it can remain focused on its areas of expertise in e-commerce and technology, and further expand on the products and services that can be provided through Cannmart.

Namaste operates the largest global online marketplace for cannabis consumption devices, with over 1.5 million customers globally. The Company has acquired and developed industry-leading technology including its e-commerce AI platform, Findify.io ("Findify") and NamasteMD ("NamasteMD.com"), which is Canada's first medical cannabis consultation app available in both the Apple and Google Play Stores. The Company plans to leverage its e-commerce technology and expertise to provide a unique user experience for each customer. Medical patients acquired through NamasteMD will be able to onboard and purchase products through Cannmart.

With Namaste's operations in over 20 countries and consumer databases established in strategic regions including the United Kingdom and Australia, the Company is well-positioned to expand on its cannabis platform in launching telemedicine and cannabis e-commerce platforms in global markets where the company maintains strong market share.

https://technical420.com/cannabis-article/cannmart-receives-health-canadas-first-acmpr-sales-only-license

petra129
Bild des Benutzers petra129
Offline
Zuletzt online: 19.05.2019
Mitglied seit: 10.11.2015
Kommentare: 139
7 Cannabis Industry Updates

7 Cannabis Industry Updates Investors Need To Know

HEXO Corp. (HEXO.TO) (HYYDF)

Organigram Holdings Inc. (OGI.V) (OGRMF)

The Supreme Cannabis Company (FIRE.V) (SPRWF)

Canopy Growth Corporation (WEED.TO) (CGC)

Emerald Health Therapeutics, Inc. (EMH.V) (EMHTF)

Choom (CHOO.CN) (CHOOF)

Invictus MD Strategies (GENE.V) (IVITF)

https://technical420.com/cannabis-article/7-cannabis-industry-updates-in...

petra129
Bild des Benutzers petra129
Offline
Zuletzt online: 19.05.2019
Mitglied seit: 10.11.2015
Kommentare: 139
wie geht...

17. Oktober ...wie geht es jetzt wohl weiter? buy on rumours sell on news? ich hoffte es gehe gestern noch einmal tüchtig hoch - war nix!

 

Ben
Bild des Benutzers Ben
Offline
Zuletzt online: 17.05.2019
Mitglied seit: 11.01.2010
Kommentare: 628
Aurora & Co

Erneute Rallye bei Cannabis-Aktien Tilray, Aurora Cannabis & Co – das sind die Gründe.

 

http://www.deraktionaer.de/aktie/erneute-rallye-bei-cannabis-aktien-tilray--aurora-cannabis---co---das-sind-die-gruende-403580.htm

 

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 16.05.2019
Mitglied seit: 16.04.2010
Kommentare: 1'415
Aurora on th NYSE

http://www.aktiencheck.de/exklusiv/Artikel-Aurora_Cannabis_Listing_NYSE_steht_bevor_Aktienanalyse-9062669

News von Aurora:

Aurora Cannabis Announces Application to List on the NYSE

EDMONTON, Oct. 9, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM), announced today that the Company has filed an application to list its common shares on the New York Stock Exchange ("NYSE").

Listing of the Company's common shares on the NYSE remains subject to the approval of the NYSE and the satisfaction of all applicable listing and regulatory requirements. Aurora anticipates that, subject to receipt of all required approvals, trading in its common shares on the NYSE will commence before the end of October 2018. In advance of the intended listing, the Company has filed a Form 40-F Registration Statement with the United States Securities and Exchange Commission.

Aurora's shares will trade on the NYSE under ticker symbol "ACB", the same symbol the Company's common shares currently, and will continue to, trade under on the Toronto Stock Exchange (TSX). Aurora will also continue to trade on the OTCQX under the ticker symbol "ACBFF" until completion of the NYSE listing. Upon receipt of all required approvals and completion of the formal listing process, the Company will publicly announce its first trading date on the NYSE. Aurora furthermore intends to voluntarily delist its shares from the OTCQX at such time.

"Through our NYSE listing, Aurora joins an established group of mature global brands with improved access and exposure to an engaged international institutional investor audience," said Terry Booth, CEO of Aurora. "Aurora's high-paced execution has made it one of the world's leading cannabis companies. We have grown from being a licensed producer with a single facility, to a horizontality differentiated and vertically integrated global organization with a funded production capacity in excess of 500,000 kg a year, sales and operations on five continents, and a team of more than 1,500 employees."

Mr. Booth added: "Our purpose-built, indoor grow facilities, designed to meet the stringent requirements for furnishing product to international markets, have made Aurora the largest supplier of medical cannabis in Europe. We are also well-prepared for the launch of the domestic adult consumer use market in Canada with a portfolio of strong consumer brands and coast-to-coast provincial supply arrangements covering 98% of the Canadian population. I am proud of our achievements to date, and look forward to updating the investor community as we continue to execute on our aggressive growth strategy."

About Aurora 

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 18 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at ultra-low costs. Intended to be replicable and scalable globally, these production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and ultra-low per gram production costs. Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland (formerly Pedanios), have achieved this level of certification.

In addition to the Company's rapid organic growth and strong execution on strategic M&A, which to date includes 15 companies – MedReleaf, CanvasRX, Peloton Pharmaceutical,  Aurora Deutschland (formerly Pedanios), H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, Agropro, Borela, and the pending acquisition of ICC Labs – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: The Green Organic Dutchman Holdings Ltd. (TSX: TGOD), Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Namaste Technologies Inc. (TSXV: N), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website, investor.auroramj.comTwitterFacebook or Instagram

Terry Booth, CEO
Aurora Cannabis Inc.  

Ben
Bild des Benutzers Ben
Offline
Zuletzt online: 17.05.2019
Mitglied seit: 11.01.2010
Kommentare: 628
Große Getränkehersteller entdecken Cannabis

Getränkegiganten, die einen Hanf-Boom unterstützen. 
Die Milliarden-Dollar-Getränkegiganten haben ihre Augen auf eine völlig neue Industrie gerichtet, eine Branche, von der sie befürchten, dass sie sie bald verschlingen wird, wenn sie nicht weiterkommt.

Also, wenn du denkst, dass du den Cannabisboom verpasst hast ... Jetzt ist vielleicht die Zeit für dich, rein zu kommen.

Quelle:

http://www.baystreet.ca/articles/stockstowatch/42544/Beverage-Giants-Backing-A-Cannabis-Boom

Nebenbei noch ein Artikel aus dem heutigen Aktionär

http://www.deraktionaer.de/aktie/aurora-cannabis--der-countdown-laeuft--400420.htm

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 16.05.2019
Mitglied seit: 16.04.2010
Kommentare: 1'415
Aurora interessant

 

Da hat noch jemand das Potential gesehen, Artikel von gestern,Dienstag - einfach mal anschauen...

Aurora Cannabis May Be About To Go Ballistic

Oct. 2, 2018 2:28 PM ET

Summary

It wouldn't surprise me to see its share price double by the end of 2018.

The company will soon be listed on a major exchange, attracting much more investment.

Upcoming Canadian legalization will be a major tailwind for Aurora.

Latest earnings confirm company's strategy and execution is paying off.

source: Seeking Alpha

Aurora Cannabis (OTCQX:ACBFF) has a lot going for it as the macro elements in the industry are favorable to the company, even as its strategy is paying off for shareholders, evidenced by its latest quarter, where it produced some great numbers.

With its large production capacity, the upcoming legalization of cannabis in Canada, the announcement it will soon be listed on a major U.S. exchange, its improved performance, and growing interest from large companies outside the sector, I believe Aurora Cannabis could at least double by the end of 2018.

Latest numbers

Revenue in the 2018 fiscal fourth quarter came in at $19.1 million, up 19 percent sequentially, and 223 percent year-over-year, beating the $18 million in revenue generated for all of fiscal 2017.

Full-year revenue was reported at $55.2 million, up over 200 percent over 2017, with revenue from cannabis accounting for $42.8 million of that, a gain of 169 percent.

Medical cannabis gross margin jumped to 74 percent, up from the 58 percent in the same reporting period last year. The company attributed that to higher dried cannabis prices and a improved product mix that included more oil products that enjoy higher prices. Oils sales accounted for over 31 percent of revenue in the reporting period, up 20 percent from the prior quarter.

The average net selling price of dried cannabis per gram for full-year 2018 increased from $6.47 last year to $7.65 per gram.

petra129
Bild des Benutzers petra129
Offline
Zuletzt online: 19.05.2019
Mitglied seit: 10.11.2015
Kommentare: 139
Pot stocks take a hit as

Pot stocks take a hit as infamous short seller targets the space

https://www.youtube.com/watch?v=hlLLk9CvjbU

....bezieht sich noch auf CRONOS ....also nicht ganz frisch - aber ich meine hörenswert, Andrew Left der Shortseller hat mich einiges gekostet...

 

Ben
Bild des Benutzers Ben
Offline
Zuletzt online: 17.05.2019
Mitglied seit: 11.01.2010
Kommentare: 628
Interessante Neuigkeit, wobei sich ja sehr viel tut,auch in USA
Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 16.05.2019
Mitglied seit: 16.04.2010
Kommentare: 1'415
Aurora-News

Yea, ich habe mich auch gefreut, nun hier noch was von Aurora/ACB. Nun, sie wollen ja auch an die Nasdaq - bei CGC/WEED ging es gut bisher. Man muss wohl einfach gut aufpassen wie die US-Polit-Winde sich drehen. Aber ich denke, die Geschäftsleitungen haben ein Ohr dorthin. Good luck for all..

https://www.thestar.com/news/cannabis/2018/09/25/aurora-cannabis-says-it-is-more-than-ready-for-consumer-legalization-on-oct-17.html

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 06.05.2019
Mitglied seit: 06.06.2011
Kommentare: 692
Aurora / Ergebnis

Emil hat am 25.09.2018 08:50 geschrieben:

Danke at Shanik82 für Info oben.

Aurora s. Link, Text ist lang, aber super  *clapping*:

https://www.newswire.ca/news-releases/aurora-cannabis-inc-announces-results-for-the-fourth-quarter-and-2018-fiscal-year-694175781.html

 

Presse / Kurzfassung:

By

Published: Sept 24, 2018 6:10 p.m.  

Tech reporter

Aurora Cannabis Inc. ACBFF, +2.64% ACB, +3.63% released fiscal fourth-quarter earnings late Monday and confirmed its intention to list stock on a "senior" U.S. exchange such as the Nasdaq or the New York Stock Exchange. "Listing our shares on a senior U.S. exchange reflects the level of corporate and business maturity and our high-paced execution," Aurora Chief Executive Terry Booth said. "This listing provides access to a broader investor audience who gain the opportunity to participate in our continued success." The company's top line grew 223% to C$19.1 million, up from C$5.9 million in the year-earlier quarter. Aurora logged earnings of C$79.9 million, up from losses of C$4.8 million in last year's quarter; in its financial statements Aurora said the quarter's profits were related to unrealized non-cash gains on derivatives and other marketable securities. Gross profit was C$20.6 million, up from C$5.8 million in the year-ago quarter. The company said it produced 2,212 kilograms of pot and sold 1,617 kilograms, up 90% and 114% respectively compared with the year-earlier period. Aurora stock is listed on the pink sheets in the U.S. and on the TSX. Toronto-listed shares have gained 28% this year, as the S&P 500 index SPX, -0.35% rose 9.2%.

Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.

Quelle:https://www.marketwatch.com/story/aurora-cannabis-releases-earnings-confirms-us-listing-plans-2018-09-24?mod=newsviewer_click

 

Danke @ Emil für Info

Ist echt gut gekommen  SmileDrinksDirol , hier noch was:

https://www.newswire.ca/news-releases/aurora-cannabis-partners-with-elevate-to-create-cannabis-education-tracks-featuring-industry-leaders-694257241.html

 

logn
Bild des Benutzers logn
Offline
Zuletzt online: 19.10.2018
Mitglied seit: 01.03.2013
Kommentare: 340
Auswertung kanadische Lizenzen

Nach langer Zeit melde ich mich auch wieder mal zu Worte.... Falls jemand eine Auswertung von sämtlichen kanadischen Lizenzen benötigt, kann sich gerne bei mir melden.

 

Ben
Bild des Benutzers Ben
Offline
Zuletzt online: 17.05.2019
Mitglied seit: 11.01.2010
Kommentare: 628
ACB & Co.

@Petra, den Blick nach vorne richten und nicht mehr dem Verpassten hinterher jammern. Es gibt so viele Möglichkeiten; eine davon ist eben Aurora. Das Listing für die NYSE ist für Ende Oktober geplant, dann sollte es nochmals einen Kursschub nach oben geben. Lassen wir uns überraschen. Und danke für den Link.

@Lorenz, danke für den Link.

Derzeit wird man überhäuft mit Informationen. Viele Medien schreiben über die neu entstandenene Industrie, sprich über den Cannabis-Sektor. Und so möchte ich auch nochmal etwas hinzufügen.

https://www.finanzen.net/nachricht/aktien/uplisting-mit-folgen-aurora-cannabis-bald-an-der-nyse-kommt-jetzt-der-tilray-effekt-6713926

Einen schönen Tag und viel Erfolg beim Investieren.

 

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 16.05.2019
Mitglied seit: 16.04.2010
Kommentare: 1'415
Aurora-News ACB

Danke euch, habe auch noch was,

ganz frisch:

Aurora Cannabis Receives Sales License for Aurora Sky Facility

Softgel Sales License Granted at Aurora Vie - New Licenses Significantly Increase Product Availability for Medical and Adult Consumer-Use Markets

EDMONTON, Oct. 17, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that its Aurora Sky ("Sky") facility has been granted its sales license by Health Canada, significantly increasing availability of both dried flower and derivative cannabis products across all cannabis markets the Company is targeting.

The Company also announced today that it has received a sales license from Health Canada, permitting the sale of cannabis softgel capsules produced at its state-of-the-art Aurora Vie facility located in Pointe-Claire, Québec. Aurora and Capcium Inc. ("Capcium"), the Montreal-based manufacturer that specializes in high-volume softgel encapsulation have already commenced production of softgel capsules, which are targeted at the medical, wellness, and adult consumer use markets. The Company anticipates softgels to become a high volume, high margin product within all of its target markets. The Company holds a 19.99 per cent ownership stake in Capcium and is Aurora's exclusive manufacturer of cannabis softgel products in North America.

"These new sales licenses are a game changer for Aurora, dramatically increasing product availability and positioning us well to serve the rapidly growing domestic and international cannabis markets," said Terry Booth, CEO of Aurora. "With adult consumer use sales beginning in Canada today, these additional licenses enable Aurora to rapidly scale-up production to service the high growth anticipated for this new market. As the first of our "Sky Class" facilities, Aurora Sky is substantially differentiated from traditional indoor and greenhouse grow facilities because of its use of advanced technologies and automation that deliver industry-leading yields. This allows us to consistently produce an abundant supply of high-quality cannabis and derivatives at sustainably low production costs, anticipated to be well below $1 per gram."

Mr. Booth added: "We're exceptionally proud of our team's efforts in completing these milestones and look forward to accelerating our growth as our facilities continue to ramp-up to full capacity."

Strategically located at the Edmonton International Airport, Aurora Sky is the world's largest and most technologically advanced cannabis hybrid-indoor production facility constructed to date. Designed by Aurora Larssen Projects and built to EU GMP specifications, the facility measures 800,000 square feet, and incorporates a high degree of automation, full control of environmental variables, and sophisticated yield optimizing technologies, to produce consistent, high-quality, medical grade cannabis at sustainably low production costs. 

Aurora Sky, which received its first production license in January, is rapidly ramping up to full capacity of over 100,000 kg per annum, which the Company anticipates reaching around year end. At full capacity, the Company anticipates one harvest every 3.5 days, resulting in over 6 harvests per room per year, comparing very favorably with traditional greenhouses and other grow facilities. In addition to cultivation, Aurora Sky also features processing, bottling, and automated packaging and labeling capacity, enabling the Company to service market demand for high margin derivative products.

To date, the mother room and four flower rooms, each measuring 34,000 square feet, have been licensed for production. The rooms have now been populated using the automated systems, which were commissioned successfully. Presently, approximately 120,000 plants are growing in the facility's licensed flower rooms. The Company has submitted license applications for additional flower rooms and all ancillary system rooms, and will be applying for further production licenses until the entire facility is licensed and populated, anticipated for late November or early December.

About Aurora 

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 18 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at ultra-low costs. Intended to be replicable and scalable globally, these production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and ultra-low per gram production costs. Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland (formerly Pedanios), have achieved this level of certification.

In addition to the Company's rapid organic growth and strong execution on strategic M&A, which to date includes 15 companies – MedReleaf, CanvasRX, Peloton Pharmaceutical,  Aurora Deutschland (formerly Pedanios), H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, and MED Colombia, Agropro, Borela, and the pending acquisition of ICC Labs – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website: investor.auroramj.com

Terry Booth, CEO  
Aurora Cannabis Inc. 

 

Presse.

Aurora Cannabis celebrates Canadian pot legalization

2018-10-17 08:59 ET - News Release

Ms. Heather MacGregor reports

AURORA CANNABIS CELEBRATES ADULT CONSUMER LEGALIZATION IN CANADA

On this historic day, Aurora Cannabis Inc. is proud to celebrate consumer legalization by commending governments of all levels for their commitment to bringing an end to the prohibition of cannabis for adult consumer use, and acknowledging the decades of activism and effort that have led to this moment.

With retail sales beginning in provinces across the country today, Canada is the first G20 country to take this historic, transformative step. The country now stands as the world leader in cannabis public policy, innovation and acceptance.

"It's a proud day to be Canadian," said Aurora chief executive officer Terry Booth. "For the last three years, the world has watched as we prepared for legalization as an industry and a country. The end of prohibition is a victory for advocates, for activists, for science, for personal freedom and for common sense. The Canadian cannabis community is strong, smart and resilient. Aurora respect and honour the will of advocates and activists who fought and continue to fight unjust laws that limited the righteous adult access to cannabis.

Aurora is one of Canada's leading licensed producers and a developer of high-quality cannabis products to markets across the country and around the world. This thriving new Canadian industry has created jobs and prosperity across Canada and Canada is setting the global standard in crop production, product quality, cannabis science and patient care.

Global leaders

Canada has now become the second country in the world following Uruguay to fully legalize adult consumer cannabis. On the medical side at least 31 countries around the world have federally regulated medical cannabis.

"Today is a day the world will not soon forget," said Neil Belot, Aurora's chief global business development officer. "Canada has taken an evidence-based approach to legalization after nearly a century-long misstep, and as a result we have made our great country a healthier and safer place for our families, communities and international visitors. We call on our cannabis advocates around the world to follow Canada's lead. Aurora's science team will continue to support and advance evidence-based, sensible, public-health approaches to all forms of cannabis policy, particularly as it relates to the commercial, food-based, wellness, medical, research and adult consumer use sectors."

Medical cannabis comes first at Aurora

While legalization of cannabis for adult consumer use is an exciting milestone, as Canada's leading licensed producer of medicinal cannabis, together with wholly owned subsidiaries CanniMed and MedReleaf, Aurora reconfirms its commitment to its medical patients, including the Canadian veteran community.

"Cannabis as a medicine is a need, not an option," said Aurora's chief corporate officer Cam Battley. "Our goal will always be to provide our patients with the greatest choice and flexibility in reliable, high-quality cannabis. We also commit to working with advocates, industry and governments across Canada to push for tax fairness for medical cannabis, something of critical importance to patients with chronic health conditions who find symptom relief in medical cannabis, but who often lack sufficient funds to afford the medication that helps them most."

Aurora and MedReleaf consumer brands available across Canada

Aurora is proud to work with government and private retailers across Canada to supply a broad range of dried flower and higher margin products such as prerolls, oils and capsules. Aurora's integrated teams and its strategic partners have entered into supply arrangements with provinces and territories accounting for more than 98 per cent of the Canadian population. The Aurora and MedReleaf brands, including San Rafael '71 and AltaVie, are expected to have a strong presence across the country, positioning the company well for rapid growth.

"We are proud of the science and innovation that have gone into developing our adult-use brands and expect them to resonate well with consumers across Canada," said Darren Karasiuk, executive vice-president, global adult usage. "Both Aurora and MedReleaf have developed expertise and technology to consistently grow premium-grade cannabis for discerning adults and we are confident that adult consumers will soon see how we differentiate ourselves from the others."

Continued outreach and education

Over the last few years, Aurora has provided comprehensive outreach, counseling and educational services to patients and physicians in the Canadian medical system through its wholly owned subsidiary CanvasRx.

Mr. Booth added: "With adult consumer use sales beginning today, our efforts to provide much needed product education and services to patients, consumers, physicians, pharmacists and retail operators will continue in earnest. New cannabis consumers, and those with limited past experience, will require comprehensive, practical information on the effects of various cannabis products, and the responsible, informed use of them."

About Aurora Cannabis Inc.

Headquartered in Edmonton, Alta., Canada, with financed capacity in excess of 500,000 kilograms per annum and sales and operations in 18 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved.

petra129
Bild des Benutzers petra129
Offline
Zuletzt online: 19.05.2019
Mitglied seit: 10.11.2015
Kommentare: 139
@Ben - bleibe auch drin, habe

@Ben - bleibe auch drin, habe leider die üblichen Fehler gemacht ---> rein-raus-rein, anstatt bei Canopy drin zu bleiben....na ja

unter diesem link einige interessante Artilel:

https://www.marketwatch.com/story/a-guide-to-pot-stocks-what-you-need-to...

A guide to pot stocks: What you need to know to invest in cannabis companies

By

Published: Oct 17, 2018 10:08 a.m. ET

 

 

Ben
Bild des Benutzers Ben
Offline
Zuletzt online: 17.05.2019
Mitglied seit: 11.01.2010
Kommentare: 628
ACB & Co.

petra129 hat am 17.10.2018 12:03 geschrieben:

 

17. Oktober ...wie geht es jetzt wohl weiter? buy on rumours sell on news? ich hoffte es gehe gestern noch einmal tüchtig hoch - war nix!

 

Derzeit wird erstmal mächtig in Canada verkauft. Gewinnmitnahmen. Abwarten wie es sich weiter entwickelt, denke ich, ist wohl momentan das Beste.

Bin dabei, bleibe dabei, denn der Cannabis-Sektor ist und bleibt spannend. Hier tut sich sehr viel und die Zukunftsaussichten sind mMn rosig.

Viel Erfolg den Investierten.

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 06.05.2019
Mitglied seit: 06.06.2011
Kommentare: 692
ACB

Danke euch. Hier noch etwas zu ACB/Aurora:  Dirol

Aurora in the Media: Your Money Australia

Cam Battley, CCO, appears on Your Money to discuss the medical cannabis system in Australia and the country’s potential to become a global industry leader alongside Canada. Also discussed is Cann Group, Australia’s leading LP and partner to Aurora, and its plans to not only supply medical cannabis to the domestic market, but to ultimately become an exporter.
Click here to watch the video.

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 16.05.2019
Mitglied seit: 16.04.2010
Kommentare: 1'415
ACB-Info

Danke @ Ben für deine Infooben.

 

Ich habe noch was von Aurora für die es interessiert am Montag, Nebenbei,ich glaube, da sollte man gut hinschauen, wer noch nicht hat, könnte etwas davon erwerben. - Und wer auf Canopy steht (WEED) der sollte ebenfalls mal ein Auge drauf haben.

EDMONTON, Nov. 8, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM), today announced that it has scheduled its conference call to discuss the results for its first quarter ended September 30, 2018. The call will be hosted on Monday, November 12th, 2018 at 10:30 a.m. Eastern Time by Terry Booth, Chief Executive Officer, Glen Ibbott, Chief Financial Officer, and Cam Battley, Chief Corporate Officer followed by a question and answer period.
 

CONFERENCE CALL DETAILS
Date: Monday, November 12th, 2018
Time: 10:30 a.m. Eastern Time (8:30 a.m. Mountain Time)
Webcast: https://bit.ly/2yX5sMk
Replay: (416) 849-0833 or (855) 859-2056
Available until 12:00 midnight Eastern Time Monday, November 19, 2018
Reference Number:1792668

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 19 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

About Aurora 

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification.

In addition to Aurora's rapid organic growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and the pending acquisition of ICC – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX and NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website, investor.auroramj.com 

Terry Booth, CEO
Aurora Cannabis Inc.
 

 

petra129
Bild des Benutzers petra129
Offline
Zuletzt online: 19.05.2019
Mitglied seit: 10.11.2015
Kommentare: 139
Aurora & Co.

Canada's pot shortage could last up to 3 years, executives warn

Kristine Owram, Bloomberg News

Canada’s pot shortage could last as long as three years, according to industry executives who say production estimates are too rosy.

Shortages have plagued the country since recreational marijuana was legalized in October. In response, Quebec’s government-controlled stores have closed three days a week, Alberta has temporarily stopped issuing retail licenses and Ontario has said it will initially open just 25 stores across Canada’s most populous province....

......Aurora Cannabis Inc. said Tuesday it expects to report fiscal second-quarter revenue of $50 million to $55 million, below the consensus estimate of $67.4 million. Aurora fell 4.1 per cent to $6.71 in Toronto at 11 a.m.

https://www.bnnbloomberg.ca/canada-s-pot-shortage-could-last-up-to-3-yea...

petra129
Bild des Benutzers petra129
Offline
Zuletzt online: 19.05.2019
Mitglied seit: 10.11.2015
Kommentare: 139
Trump Signs 2018 Farm Bill

Trump Signs 2018 Farm Bill

By

Chuck Abbott

12/20/2018

Michael Vadon

President Trump signed into law the 2018 farm bill that modestly strengthens the farm safety net, loosens farm subsidy rules, and legalizes industrial hemp as a crop and then announced he was taking “immediate action on welfare reform” through stricter enforcement of time limits on food stamps to able-bodied people on Thursday.....

https://www.agriculture.com/news/business/trump-signs-2018-farm-bill

...ist schon nicht so prickelnd - sobald es legal wird sausen die Aktien runter, war in Kanada auch so

Selector
Bild des Benutzers Selector
Offline
Zuletzt online: 06.05.2019
Mitglied seit: 06.06.2011
Kommentare: 692
Infos

Smile  Dirol  Da sollte man wohl in der Branche mindestens mit einem Bein drin sein / bleiben:

 

HINTERGRUND-Nach der Potcom-Blase - Cannabis-Branche wird erwachsen 19-12-2018 15:29

* Cannabis-Branche wächst dank zunehmender Legalisierung

* Getränke- und Tabakindustrie investiert Milliarden

* Aktien sind nach Rekordwerten im Herbst aber auf Talfahrt

- von Patricia Weiss

Frankfurt, 19. Dez (Reuters) - In der Cannabis-Branche herrscht Goldgräberstimmung. Anleger, die ihr Geld in börsennotierte Produzenten wie Canopy Growth und Aurora Cannabis steckten, konnten sich in den vergangenen zwei Jahren eine goldene Nase verdienen. Inzwischen ist etwas Ernüchterung eingekehrt: Seit Kanada im Oktober als weltweit erste große Industrienation den Cannabis-Konsum vollständig freigab, gingen die Kurse nach unten, auch wegen schwächer als erwarteter Geschäftszahlen. "Die Aktien waren ein absoluter Spielball von Zockern", sagt Analyst Jochen Stanzl vom Broker CMC Markets. Dieser Hype sei vorbei. "Die Frage ist nun, wie sich die Unternehmen dieser Branche etablieren." Denn auch wenn sich Anleger 2019 dem nächsten Trendthema zuwenden dürften, sind sich Experten einig: Die Cannabis-Industrie ist auf Wachstumskurs, die Nachfrage ist riesig - als Genussmittel sowieso, aber immer mehr auch zu medizinischen Zwecken.

Seit Anfang 2017 bis zu den Höchstständen im Oktober dieses Jahres legten die Aktien von Branchengrößen wie Canopy Growth und Aurora Cannabis um 670 Prozent beziehungsweise 650 Prozent zu. Seitdem haben die Aktien der Cannabis-Firmen an der Börse aber teilweise mehr als die Hälfte an Wert eingebüßt. Der nordamerikanische "Marijuana Index", in dem die führenden Unternehmen der Branche aus den USA und Kanada gelistet sind, hat seit seinem Rekordhoch im Herbst rund die Hälfte verloren. CMC-Analyst Stanzl spricht von einer Blase, die geplatzt ist. "Von der Psychologie war das vergleichbar mit Bitcoin." Für einen digitalen Taler mussten Anleger vor einem Jahr knapp 20.000 Dollar auf den Tisch legen, inzwischen kostet Bitcoin gerade noch 3200 Dollar.

Einig sind sich Experten aber, dass es sich bei Cannabis im Gegensatz zum Bitcoin um ein echtes Produkt mit großem Marktpotenzial handelt. "Bei den großen kanadischen Herstellern haben wir erstaunliche Wachstumsraten gesehen. Das wird in der Geschwindigkeit möglicherweise nicht so weitergehen, aber es wird aus meiner Sicht zu weiterem signifikantem Wachstum kommen", sagt Peter Homberg, Partner und Leiter der Life-Science-Praxis bei der Wirtschaftskanzlei Dentons.

Auch Marktforscher zeichnen ein positives Bild und überbieten sich in ihren euphorischen Prognosen: Bis 2022 dürften die weltweiten Ausgaben für legales Marihuana nach Einschätzung von BDS Analytics und Arcview auf 32 Milliarden Dollar steigen, 2017 waren es noch 9,5 Milliarden. 41 Prozent dürften bis dahin alleine auf Kanada und Kalifornien entfallen. Kalifornien zählt zu einer Reihe von US-Bundesstaaten von Colorado bis Washington, in dem der Cannabis-Konsum bereits vollständig legal ist. Aber auch Europa spielt eine immer wichtigere Rolle. Dort erlauben mehr als 20 Länder medizinisches Cannabis, darunter Deutschland seit März 2017. Die Marktforscher von Prohibition Partners trauen alleine Europa bis 2028 ein Marktpotenzial von knapp 116 Milliarden Euro (knapp 132 Milliarden Dollar) zu. Das setzt allerdings eine vollständige und eher unwahrscheinliche Legalisierung auf dem gesamten Kontinent voraus.

 

GENUSSMITTEL ODER SCHMERZKILLER

Welche Unternehmen können am meisten Geschäft abschöpfen? Zu den Erfolgsfaktoren zählen nach Einschätzung der Analysten der Berenberg Bank Größe, Produktvielfalt, Marken sowie der Marktzugang. Dabei sehen sie Canopy Growth am besten positioniert, sowohl auf dem Heimatmarkt Kanada als auch international. Das Unternehmen hat zudem einen starken Partner im Rücken: Der Corona-Bier-Hersteller Constellation Brands pumpte im August vier Milliarden Dollar in Conopy und baute seinen Anteil auf 38 Prozent aus. Zusammen wollen die beiden Firmen cannabishaltige Getränke entwickeln - ein Trend, den auch Coca Cola nach eigenen Angaben genau beobachtet. Dem weltgrößten Getränkekonzern wurde Interesse am Canopy-Rivalen Aurora nachgesagt. Einen Schritt weiter ist bereits der Tabakkonzern Altria. Der Marlboro-Hersteller stieg kürzlich bei dem kanadischen Produzenten Cronos für 1,8 Milliarden Dollar ein.

Während Nordamerika bei der Legalisierung von Cannabis als Genussmittel eine Vorreiterrolle einnimmt, steht in Europa die Freigabe zu medizinischen Zwecken im Fokus. Erst im November legalisierte Großbritannien medizinisches Cannabis. Die Wirkstoffe können unter anderem Schmerzen bei Krebserkrankungen, Übelkeit nach Chemotherapien oder Spastiken bei Multipler Sklerose lindern. "Wir sehen eine starke Entwicklung hin zur medizinischen Verwendung in allen möglichen Ländern, das ist ein riesiges Potenzial", ist sich Georg Wurth, Geschäftsführer beim Deutschen Hanfverband, sicher. Nach seinen Schätzungen gibt es in Deutschland rund 30.000 Patienten, die Cannabis von der gesetzlichen Krankenkasse erstattet bekommen, Tendenz steigend. Bislang wird der hiesige Bedarf noch über Importe gedeckt. Erst ab 2020 dürfte nach Einschätzung des Bundesinstitut für Arzneimittel und Medizinprodukte Cannabis auch aus Anbau in Deutschland zur Verfügung stehen. Das Institut hat Aufträge zur Produktion von medizinischem Cannabis in Deutschland ausgeschrieben, die Bewerbungsfrist dafür endete erst vor wenigen Tagen.

(Mitarbeit von Patricia Uhlig, redigiert von Kathrin Jones. Bei Rückfragen wenden Sie sich bitte an die Redaktionsleitung unter den Telefonnummern 069-7565 1232 oder 030-2888 5168.) ((patricia.weiss@thomsonreuters.com; +49 69 7565 1337; Reuters Messaging: patricia.weiss.reuters.com@reuters.net, www.twitter.com/REUTERS_DE, www.reuters.de))

Quelle Swissquote

 

Seiten